Skip to main content
Premium Trial:

Request an Annual Quote

Frances Heller, Ronald Marler, Mark Wdowik

Premium
Exelixis has appointed Frances Heller as executive vice president of business development, the company said last week.
 
Heller joins Exelixis from the Novartis Institutes for Biomedical Research, the global research organization for Novartis AG, where she was head of strategic alliances. Previously, she served as vice president of corporate development and legal affairs at Signature BioScience; and corporate and intellectual property counsel for Celera Genomics.
 
Heller received a JD from the Golden Gate University School of Law and an MA in biology from American University.
 

 
CSU Ventures, the non-profit business-development arm of Colorado State University, said last week that Ronald Marler has been appointed as CEO.
 
Marler is currently a board member of CSU Ventures. In his new role, he will work closely with Mark Wdowik, who has served as inaugural CEO of the corporation since February 2007. Wdowik will now be responsible for launching a CSU for-profit seed investment fund, which will invest in CSU start-ups and key research partners.
 
Marler has more than 30 years of experience in the pharmaceutical research and product development fields, CSU said. He is currently a senior administrator at Mayo Clinic Arizona, and CSO and board member of Bridge Laboratories. He received a BS, DVM, and PhD from Kansas State University.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.